Skip to content
Medical Health Aged Care

Dementia Australia supports Yea, Alexandra, Eildon and Kinglake

Dementia Australia 2 mins read

Are you concerned about your memory or worried that someone you know may have dementia? Dementia Australia is offering support in Yea between 2 and 5 December. 

 

It is estimated there are almost 110,600 people living with dementia in Victoria. Without a medical breakthrough this number is expected to increase to more than 216,400 people living with dementia by 2054. 

 

The Dementia Australia sessions are an opportunity for people living with dementia, their carers, family, and friends to attend free education to better understand dementia and to discuss the support and services Dementia Australia can provide. Please note, bookings are essential. 

 

 
Community Information Session 

This session provides information on memory and common changes that may occur with ageing. It provides strategies for improving memory, when to seek help about your concerns and services provided by Dementia Australia. This session will also include a talk by Seniors Rights Victoria. 
Tuesday 2 December, 9:30am-12:30pm 
 

 
Worried About Your Memory? 

This session provides information on memory and common changes that may occur with ageing. It provides strategies for improving memory, when to seek help about your concerns and services provided by Dementia Australia. 
Wednesday 3 December, 1pm-3:30pm, Alexandra 
 

Mobile Health Van Brain Hub 
Learn about dementia and the services and support available through Dementia Australia.  

Thursday 4 December, 9:30am-11am. Eildon 
 

Mobile Health Van Brain Hub 
Learn about dementia and the services and support available through Dementia Australia.  

Thursday 4 December, 2pm-3:30pm. Kinglake 
 
Drop in sessions 
At this information session you can learn about the support and services offered by Dementia Australia, the Council on Ageing, Senior Rights Victoria, Live Up, Yea and District Memorial Hospital and Alexandra District Health.  

Friday 5 December, 9am-12pm. Yea 
 

 
 

Bookings are essential. Visit https://www.eventbrite.com.au/e/dementia-australia-brain-hub-yea-vic-registration-1903189363619 for details and to register. You can also call the National Dementia Helpline to register for this course on 1800 100 500. The National Dementia Helpline is available 24 hours a day, seven days a week. 

 

 

Dementia Australia is the source of trusted information, education and services for the estimated 433,300 Australians living with dementia, and the estimated 1.7 million people involved in their care. We advocate for positive change and support vital research. We are here to support people impacted by dementia, and to enable them to live as well as possible. No matter how you are impacted by dementia or who you are, we are here for you. 

For support, please contact the National Dementia Helpline on 1800 100 500. An interpreter service is available. The National Dementia Helpline is funded by the Australian Government. People looking for information can also visit dementia.org.au  

Media contacts: [email protected], 0435 515 221                               

When talking or writing about dementia please refer to Dementia-Friendly Language Guidelines. 

Note to Editors: We request, where possible, details for the National Dementia Helpline 1800 100 500 appear alongside news stories about dementia, as these stories often prompt questions or concerns:  

If this story has prompted any questions or concerns, please call the National Dementia Helpline 1800 100 500 (24 hours, 7 days a week) or visit dementia.org.au.  

Media

More from this category

  • Medical Health Aged Care
  • 07/12/2025
  • 01:41
Takeda Pharmaceutical Company Limited

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline NEWARK,…

  • Medical Health Aged Care
  • 06/12/2025
  • 02:11
Arthur D. Little

Arthur D. Little and Vega IT Unveil Joint Venture for Digital Innovation

NEW YORK–BUSINESS WIRE– Arthur D. Little (ADL) and Vega IT today announced the formation of Axceler8 Solutions, a 50/50 joint venture created to design,…

  • Contains:
  • Medical Health Aged Care, Women
  • 05/12/2025
  • 10:11
Breast Cancer Trials

Bec’s Christmas wish amid cancer treatment

This Christmas, Bec’s wish is for her daughters to never face a breast cancer diagnosis like she has. “The only thing tougher than telling…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.